These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18841028)

  • 61. High sustained virologic response rate after interferon monotherapy in Japanese hepatitis C patients with a low HCV RNA titer and/or HCV genotype 2. A prospective study.
    Yokosuka O; Iwama S; Suzuki N; Takashi M; Hirai Y; Uchiumi K; Kimura M; Gotou N; Hino S; Hayasaka A; Kanda T; Kawai S; Fukai K; Imazeki F; Saisho H
    Intervirology; 2004; 47(6):328-34. PubMed ID: 15564744
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Interferon lambda-3 is not associated with clinical outcome in patients with HCV-induced compensated cirrhosis: a long-term cohort study.
    Bruno S; Thompson AJ; Critelli R; Crosignani A; Rossi S; De Lisi S; Cariani E; Zermiani P; Vaira V; Boccaccio V; Maisonneuve P; Villa E
    Antiviral Res; 2015 Jan; 113():27-32. PubMed ID: 25446338
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C.
    Villa E; Karampatou A; Cammà C; Di Leo A; Luongo M; Ferrari A; Petta S; Losi L; Taliani G; Trande P; Lei B; Graziosi A; Bernabucci V; Critelli R; Pazienza P; Rendina M; Antonelli A; Francavilla A
    Gastroenterology; 2011 Mar; 140(3):818-29. PubMed ID: 21167831
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prevalence of hepatitis C virus genotypes in a Spanish liver transplant unit.
    Moreno Planas JM; Fernández Ruiz M; Portero Azorin F; Boullosa Graña E; Rubio González E; Martín Garcia S; Martinez Arrieta F; Jiménez Garrido M; Sánchez Turrión V; Cuervas-Mons Martinez V
    Transplant Proc; 2005 Apr; 37(3):1486-7. PubMed ID: 15866649
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The prevalence of hepatitis B virus and hepatitis C virus infection among patients with chronic liver disease in South India.
    Saravanan S; Velu V; Kumarasamy N; Shankar EM; Nandakumar S; Murugavel KG; Balakrishnan P; Solomon SS; Solomon S; Thyagarajan SP
    Int J Infect Dis; 2008 Sep; 12(5):513-8. PubMed ID: 18455943
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [Long-term interferon (IFN), neominophagen C (SNMC) combination therapy of active liver cirrhosis type C].
    Iwabuchi S; Osada T; Takatori M; Yoshida H
    Nihon Rinsho; 1994 Jul; 52(7):1880-8. PubMed ID: 7521434
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Interferon-Free Therapy in Elderly Patients With Advanced Liver Disease.
    Lens S; Fernández I; Rodríguez-Tajes S; Hontangas V; Vergara M; Forné M; Calleja JL; Diago M; Llaneras J; Llerena S; Torras X; Sacristán B; Roget M; Fernández-Rodríguez CM; Navascués MC; Fuentes J; Sánchez-Ruano JJ; Simón MÁ; Sáez-Royuela F; Baliellas C; Morillas R; Forns X;
    Am J Gastroenterol; 2017 Sep; 112(9):1400-1409. PubMed ID: 28585554
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy.
    Kurosaki M; Matsunaga K; Hirayama I; Tanaka T; Sato M; Komatsu N; Umeda N; Hosokawa T; Ueda K; Tsuchiya K; Nakanishi H; Itakura J; Asahina Y; Miyake S; Enomoto N; Izumi N
    J Hepatol; 2008 May; 48(5):736-42. PubMed ID: 18329125
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Efficacy of interferon monotherapy to 394 consecutive naive cases infected with hepatitis C virus genotype 2a in Japan: therapy efficacy as consequence of tripartite interaction of viral, host and interferon treatment-related factors.
    Akuta N; Suzuki F; Tsubota A; Suzuki Y; Someya T; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2002 Dec; 37(6):831-6. PubMed ID: 12445425
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Outcome of antiviral therapy in Egyptian Hepatitis C Virus (HCV) genotype 4 patients with advanced liver fibrosis.
    el-Khattib AA; Abdelhakam SM; Ghoraba DM; Ibrahim WA; Sayed MM
    Eur J Intern Med; 2012 Jan; 23(1):e34-5. PubMed ID: 22153547
    [No Abstract]   [Full Text] [Related]  

  • 71. Hepatitis C virus-related cirrhosis as a significant mortality factor in intention-to-treat analysis in liver transplantation.
    Gringeri E; Vitale A; Brolese A; Zanus G; Boccagni P; Neri D; Valmasoni M; D'Amico F; Ciarleglio FA; Carraro A; Pauletto A; Violi P; Bassi D; D'Amico F; D'Amico DF; Cillo U
    Transplant Proc; 2007; 39(6):1901-3. PubMed ID: 17692648
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Interferon-alpha therapy does not modulate hepatic expression of classical type I interferon inducible genes.
    Meier V; Mihm S; Ramadori G
    J Med Virol; 2008 Nov; 80(11):1912-8. PubMed ID: 18814253
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.
    Di Marco V; Capra M; Gagliardotto F; Borsellino Z; Cabibi D; Barbaria F; Ferraro D; Cuccia L; Ruffo GB; Bronte F; Di Stefano R; Almasio PL; Craxì A
    Haematologica; 2008 Aug; 93(8):1243-6. PubMed ID: 18556410
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Viral elimination reduces incidence of malignant lymphoma in patients with hepatitis C.
    Kawamura Y; Ikeda K; Arase Y; Yatsuji H; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki F; Suzuki Y; Kumada H
    Am J Med; 2007 Dec; 120(12):1034-41. PubMed ID: 18060923
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Differences in molecular alterations of hepatocellular carcinoma between patients with a sustained virological response and those with hepatitis C virus infection.
    Hayashi T; Tamori A; Nishikawa M; Morikawa H; Enomoto M; Sakaguchi H; Habu D; Kawada N; Kubo S; Nishiguchi S; Shiomi S
    Liver Int; 2009 Jan; 29(1):126-32. PubMed ID: 18492017
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Treatment of chronic hepatitis C and alcohol consumption].
    Mathurin P; Canva V; Dharancy S; Paris JC
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B248-51. PubMed ID: 12180297
    [No Abstract]   [Full Text] [Related]  

  • 77. Outcome of liver disease in a large cohort of histologically proven chronic hepatitis C: influence of HCV genotype.
    Roffi L; Redaelli A; Colloredo G; Minola E; Donada C; Picciotto A; Riboli P; Del Poggio P; Rinaldi G; Paris B; Fornaciari G; Giusti M; Marin R; Morales R; Sangiovanni A; Belloni G; Pozzi M; Poli G; Mascoli N; Corradi C; Pioltelli P; Scalori A; Mancia G
    Eur J Gastroenterol Hepatol; 2001 May; 13(5):501-6. PubMed ID: 11396528
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C.
    Arase Y; Kobayashi M; Kawamura Y; Suzuki F; Suzuki Y; Akuta N; Kobayashi M; Sezaki H; Saito S; Hosaka T; Ikeda K; Kumada H; Kobayashi T
    J Med Virol; 2014 Jan; 86(1):169-75. PubMed ID: 24155199
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Treatment of hepatitis C in patients with cirrhosis: remaining challenges for direct-acting antiviral therapy.
    Majumdar A; Kitson MT; Roberts SK
    Drugs; 2015 May; 75(8):823-34. PubMed ID: 25943281
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Association of interferon regulatory factor-7 gene polymorphism with liver cirrhosis in chronic hepatitis C patients.
    Sermasathanasawadi R; Kato N; Muroyama R; Dharel N; Shao RX; Chang JH; Li CZ; Kawabe T; Omata M
    Liver Int; 2008 Jul; 28(6):798-806. PubMed ID: 18397234
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.